Although there are still side effects and weight fluctuations to consider, the results overall have been overwhelmingly positive and have caused great enthusiasm among doctors, patients, and investors
Glucagon-like peptide 1 receptor agonists for type 2 diabetes, Diabetes Spectrum (2017) With Trulicity, patients may be able to lose some weight, Eli Lilly Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11), Diabetes Care (2021) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial, Lancet Diabetes Endocrinology (2017) Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial, Lancet (2014) Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3), Diabetes Care (2014) Mounjaro prescribing information, Eli Lilly Beyond glycemia: Comparing tirzepatide to GLP-1 analogues, Reviews in Endocrine and Metabolic Disorders (2023) Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial, Lancet Diabetes Endocrinology (2022) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Licensed options include
A conservative estimate suggests that a 50-pound weight regain costs $5,000 to $15,000 in direct healthcare costs over the following five years through increased medications, more frequent provider visits, and management of weight-related complications
